Spatiotemporal release of VEGF from biodegradable polylactic-co-glycolic acid microspheres induces angiogenesis in chick chorionic allantoic membrane assay by Qutachi, Omar et al.
1	Introduction
Ischemic	wounds	can	be	 linked	 to	many	debilitating	diseases	such	as	myocardial	 infarction,	diabetes	mellitus	and	chronic	 limb	 ischemia.	The	damage	can	affect	a	variety	of	 tissues	 including	myocardium,	nerve,	 skin	and
skeletal	muscle.	The	ability	to	enhance	tissue	perfusion	in	an	ischemic	wound	through	re-vascularisation	is	still	 the	main	challenge	despite	the	major	advances	in	surgical	techniques	(Tenna	et	al.,	2014).	Therapeutic	angiogenesis
(Takeshita	et	al.,	1994)	is	a	promising	strategy	to	treat	ischemic	wound	diseases	which	can	be	enhanced	by	employing	VEGF	to	promote	neovascularisation	(Yoon	et	al.,	2004).	This	concept	has	attracted	many	researchers	since	the
mid-90s	and	despite	the	promising	findings	from	numerous	in	vitro	and	in	vivo	animal	studies	(Cartland	et	al.,	2016;	Takeshita	et	al.,	1994;	Yu	et	al.,	2015);	there	are	inconsistencies	from	clinical	trials	(Eppler	et	al.,	2002;	Henry	et	al.,
2001;	Kusumanto	et	al.,	2006).	This	was	attributed	to	the	short	half-life	of	VEGF	and	susceptibility	to	degradation	when	injected	directly	in	its	solution	form	(Eppler	et	al.,	2002;	Kleinheinz	et	al.,	2010).	Overcoming	this	limitation	by
increasing	the	VEGF	dose	can	be	toxic	at	high	systemic	levels	(Karvinen	et	al.,	2011;	Tayalia	and	Mooney,	2009).	Therefore,	targeted	VEGF	delivery	using	controlled	release	formulations	appears	to	be	a	better	approach	to	promote
neovascularisation	 at	 the	 target	 tissue.	 This	 type	 of	 localised	 delivery	 requires	 a	 careful	 understanding	 of	 the	microenvironment	 required	 for	 physiologic	 angiogenesis,	which	 is	 dependent	 on	 spatiotemporal	 presentation	 of	 the
delivered	VEGF	(Blau	and	Banfi,	2001).
Polymeric	materials	present	a	promising	approach	in	controlling	tissue	VEGF	presentation	at	the	target	tissue.	They	can	provide	physical	protection	of	the	payload	until	it	is	released.	This	also	includes	tailored	release	kinetics
in	term	of	timing	in	addition	to	achieving	localised	delivery	with	a	minimally	invasive	injectable	formulation	(Silva	and	Mooney,	2007).	Such	polymeric	formulations	employ	a	lower	VEGF	dose	for	achieving	a	better	outcome	in	term	of
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Abstract
While	vascular	endothelial	growth	factor	(VEGF)	is	an	acknowledged	potent	pro-angiogenic	agent	there	is	a	need	to	deliver	it	at	an	appropriate	concentration	for	several	days	to	achieve	angiogenesis.	The	aim	of	this
study	was	to	produce	microspheres	of	biodegradable	polylactic-co-glycolic	acid	(PLGA)	tailored	to	achieve	sustained	release	of	VEGF	at	an	appropriate	concentration	over	seven	days,	avoiding	excessive	unregulated	release	of
VEGF	that	has	been	associated	with	the	formation	of	leaky	blood	vessels.	Several	formulations	were	examined	to	produce	microspheres	loaded	with	both	human	serum	albumin	(HSA)	and	VEGF	to	achieve	release	of	VEGF
between	3	and	10 ng	per	ml	for	seven	days	to	match	the	therapeutic	window	desired	for	angiogenesis.	In	vitro	experiments	showed	an	increase	in	endothelial	cell	proliferation	in	response	to	microspheres	bearing	VEGF.
Similarly,	when	microspheres	containing	VEGF	were	added	to	the	chorionic	membrane	of	fertilised	chicken	eggs,	there	was	an	increase	in	the	development	of	blood	vessels	over	seven	days	in	response,	which	was	significant
for	microspheres	bearing	VEGF	and	HSA,	but	not	VEGF	alone.	There	was	an	increase	in	both	blood	vessel	density	and	branching	–	both	signs	of	proangiogenic	activity.	Further,	there	was	clearly	migration	of	cells	to	the	VEGF
loaded	microspheres.	In	summary,	we	describe	the	development	of	an	injectable	delivery	vehicle	to	achieve	spatiotemporal	release	of	physiologically	relevant	levels	of	VEGF	for	several	days	and	demonstrate	the	angiogenic
response	to	this.	We	propose	that	such	a	treatment	vehicle	would	be	suitable	for	the	treatment	of	ischemic	tissue	or	wounds.
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angiogenesis	compared	to	direct	injection	of	the	VEGF	solution	and	with	less	adverse	effects	(Eppler	et	al.,	2002).	The	following	represents	examples	of	different	polymeric	materials	that	have	been	tested	for	VEGF	targeted	delivery
include;	fibrin	gel	(Sacchi	et	al.,	2014),	hyaluronic	gel	(Chen	et	al.,	2012)	in	addition	to	PLGA	microspheres,	nanoparticles	or	scaffold	(des	Rieux	et	al.,	2011;	Jiang	et	al.,	2015;	Yu	et	al.,	2015).
PLGA	is	a	biodegradable/biocompatible,	FDA	approved	material	which	has	been	used	for	localised	growth	factors	delivery.	Depending	on	the	MW	and	lactide	to	glycolide	ration,	PLGA	release	kinetics	can	followes	biphasic
(Porporato	et	al.,	2012)	or	Triphasic	profile	(Bhardwaj	et	al.,	2008).	This	starts	with	initital	burst	release	of	the	materials	on	the	surface	of	the	microspheres	follwoedfollowed	by	a	siginifiacant	decline	with	a	lag	phase	which	may	be
followed	by	a	second	burst	release	phase	when	massive	polymer	backbone	degradation	is	reached	over	time	(Bhardwaj	et	al.,	2008;	Faranesh	et	al.,	2004).	Differen	PLGA	based	formulations	were	used	to	 induce	angiogenesis	and
enhance	wound	healing	(Chereddy	et	al.,	2015;	Lee	and	Lee,	2009;	Yu	et	al.,	2015).	However,	 this	 is	 still	wide	diversity	 in	 terms	controlling	 the	dosing,	 release	kinetics	and	 treatment	duration	 to	avoid	 limitation	 related	 to	dose
fluctuation	or	continuous	release	for	unnecessary	extended	time.
Even	with	the	highest	levels	of	spatiotemporal	control	of	VEGF	release	using	polymeric	carrier	materials,	there	is	still	a	need	for	a	better	control	to	achieve	physiological	angiogenesis	rather	than	angioma	or	aberrant	vascular
structures	(Banfi	et	al.,	2005;	Karvinen	et	al.,	2011).	During	angiogenesis,	the	niche	concentration	of	VEGF	rather	than	the	dose	will	determine	normal	or	aberrant	angiogenesis.	Therefore,	despite	the	importance	of	the	control	over
timing	and	positioning	of	VEGF	release,	the	local	VEGF	concentration	should	be	maintained	within	an	effective	concentration	range	but	bellow	supra-physiological	concentrations	to	induce	physiological	angiogenesis	(Ozawa	et	al.,
2004).
According	to	the	literature,	the	angiogenic	effect	of	VEGF	can	be	achieved	at	a	range	of	5–20 ng/mL	with	a	plateau	effect	at	50 ng/mL	(Yue	and	Tomanek,	2001).	No	further	improvement	can	be	seen	above	this	saturation	level
with	 the	 possibility	 of	 having	 aberrant	 angiogenesis	 at	 higher	 concentrations	 (Banfi	et	al.,	2005).	 Another	 important	 aspect	 is	 the	 duration	 of	 the	VEGF	 treatment,	 although	 exposure	 time	 can	 be	 extended	 for	weeks	 to	 achieve
angiogenic	effect	(Amsden	et	al.,	2010;	Bhardwaj	et	al.,	2008;	Cleland	et	al.,	2001),	a	few	days	of	localised	VEGF	treatment	can	be	enough	to	elicit	angiogenic	effect	and	wound	healing	(Chereddy	et	al.,	2015).
The	aim	of	this	study	is	to	provide	an	engineered	formulation	from	PLGA	microspheres	to	deliver	a	therapeutic	dose	of	VEGF	in	the	right	place	and	for	an	appropriate	length	of	time	to	induce	angiogenesis.	PLGA	has	a	long
history	 of	 safety	 as	 a	 biocompatible/biodegradable	material.	 The	 formulation	will	 be	 engineered	 to	 achieve	 localised	 delivery	 for	 up	 to	 seven	 days	 of	 effective	 VEGF	 concentrations	 to	 promote	 angiogenesis	 over	 an	 appropriate
therapeutic	window.	The	delivery	should	not	persist	beyond	the	period	in	which	VEGF	is	required.	Such	a	formulation	can	be	delivered	either	by	injection	for	localised	delivery	to	say	cardiac	tissue	or	by	topical	delivery	to	for	example
chronic	non-healing	ulcers.
2	Materials	and	methods
2.1	Materials
Poly(vinyl	alcohol)	(PVA,	molecular	weight:	13,000–23,000 Da,	87–89%	hydrolysed),	human	serum	albumin	(HSA),	polyethylene	glycol	 (PEG,	molecular	weight:	1500 Da),	stannous	octoate/Tin(II)	2-ethylhexanoate	 (Sn(Oct)2),
dimethyl	sulphoxide	(DMSO),	sodium	hydroxide	(NaOH),	sodium	dodecyl	sulphate	(SDS)	were	obtained	from	Sigma–Aldrich,	UK.	Poly	(D,L-lactide-co-glycolide)	(PLGA)	polymers	with	acid	end	groups	and	lactide:glycolide	ratios	of	50:50
(product	name	DLG	4A,	lot	number	LP782,	59 kDa)	and	85:15	(product	name	DLG	5A,	lot	number	LP831,	62 kDa)	were	purchased	from	Evonik,	USA.	D,	L-Lactide	and	glycolide	monomers	were	obtained	from	Lancaster	Synthesis,	Ward
Hill,	MA,	USA	and	PURAC,	Gorinchem,	Netherlands,	respectively.	The	Pierce	Micro	bicinchoninic	acid	(BCA)	protein	assay	kit	and	HPLC	grade	solvents	(dichloromethane	(DCM)	and	acetone)	were	purchased	from	Fisher	Scientific	UK
Ltd,	Loughborough,	UK.	Recombinant	human	VEGF	165	was	purchased	from	Peprotech,	UK.
2.2	Fabrication	of	microspheres
Synthesis	of	the	PLGA–PEG–PLGA	triblock	copolymer	occurred	by	ring	opening	polymerisation	of	the	D,L-lactide	and	glycolide	monomers	in	the	presence	of	PEG	and	the	(Sn(Oct)2),	catalyst	under	a	dry	nitrogen	atmosphere.
Details	regarding	triblock	polymer	synthesis	and	characterisation	can	be	found	in	White	et	al.	(White	et	al.,	2013).	In	brief,	PEG	was	dried	first	under	vacuum	and	stirring	at	120 °C	for	3 h	followed	by	temperature	increase	to	150 °C.	The
monomers	were	then	added	to	the	reaction	vessel	under	dry	nitrogen	atmosphere	and	left	to	equilibrate	for	30 min.	Then	after,	the	catalyst	was	added	and	the	reaction	was	allowed	to	proceed	for	8 h.	The	resultant	copolymer	was
dissolved	and	precipitated	in	water	to	remove	un-reacted	monomers.	The	triblock	copolymer	was	then	dried	under	vacuum	to	remove	residual	water	and	stored	at	−20 °C	until	required.	The	molecular	weight	(5886)	and	polydispersity
index	of	the	copolymer	(1.14)	were	determined	using	Gel	Permeation	Chromatography	(PL-GPC	120,	Polymer	Labs)	with	differential	refractometer	detection.	Chloroform	was	employed	as	an	eluent,	with	two	columns	(30 cm,	PolarGel-
M)	in	series	calibrated	against	polystyrene	standards.
PLGA	microspheres	were	produced	by	double	emulsion	method	from	PLGA	50:50	or	85:15+/−30%	triblock.	Briefly,	1 g	of	PLGA	or	0.7 g	PLGA	plus	0.3 g	triblock	was	dissolved	in	5 ml	DCM.	The	aqueous	solution	was	prepared
by	dissolving	9.88 mg	HSA	plus	0.12 mg	VEGF	in	100 µl	DW.	The	aqueous	solution	was	added	to	the	polymer	solution,	followed	by	homogenisation	for	two	minutes	at	9000 rpm	using	a	Silverson	L5M	homogeniser	(Silverson	Machines,
UK)	 to	 form	 the	primary	water-in-oil	 emulsion.	The	 latter	was	 then	homogenised	 in	350 ml	of	0.3%	polyvinyl	alcohol	at	2100 rpm,	 the	 resultant	water-in-oil-in-water	double	emulsion	was	 left	 stirring	 for	 four	hours	 to	 allow	DCM
evaporation.	 The	 hardened	 microspheres	 were	 harvested	 via	 series	 of	 washing	 with	 distilled	 water	 and	 centrifugation	 followed	 by	 lyophilisation	 (Edwards	Modulyo,	 IMA	 Edwards,	 UK)	 until	 dry	 then	 stored	 at	−20 °C.	 Control
microspheres	were	manufactured	with	10 mg	HSA	protein	in	100 μl	distilled	water	in	the	primary	emulsion.	Another	control	was	prepared	without	HSA,	of	120 μg	VEGF	165	in	100 μl	DW	in	the	primary	emulsion.
2.3	Scanning	electron	microscopy	(SEM)
The	surface	morphology	of	the	fabricated	particles	was	examined	using	SEM.	Microspheres	were	mounted	on	aluminium	stubs	(Agar	Scientific,	UK)	and	gold	coated	using	a	Balzers	SCD030	gold	sputter	coater	(Balzers	Union
Ltd.,	Lichtenstein)	with	an	argon	rate	of	26 mA	for	5 min.	The	structural	morphology	of	 the	microspheres	was	examined	using	a	 JEOL	6060L	scanning	electron	microscope	 imaging	system	 (JEOL	Ltd.,	Hertfordshire,	UK)	at	10 kV
ionising	radiation.
2.4	Microsphere	size	analysis
The	mean	microsphere	diameter	and	size	distribution	were	investigated	using	a	Coulter	LS230	particle	size	analyser	(Beckman,	UK).	Briefly,	50 mg/ml	in	double	deionised	water	were	sized	with	agitation	to	prevent	particle
settling.	Microsphere	size	distribution	was	then	determined	as	a	function	of	the	microsphere	diffraction	and	plotted	as	a	function	of	volume	percentage.
2.5	Entrapment	efficiency	for	total	protein
The	measurement	of	the	entrapment	efficiency	of	protein	within	the	microspheres	was	a	modification	of	techniques	proposed	by	Sah	(1997)	and	Morita	et	al.	(2001).	Briefly,	10 mg	of	PLGA	microspheres	were	added	to	750 μl
DMSO	and	left	until	the	sample	dissolved	then	2150 μl	of	0.02%	SDS	in	0.2 M	NaOH	was	added	and	left	for	1 h.	The	Micro	BCA	protein	assay	kit	was	used	to	quantify	the	total	protein	content	and	compared	against	a	standard	curve	of
HSA.	Sample	(150 μl)	and	BCA	working	reagent	(150 μl)	were	mixed	and	incubated	for	2 h	at	37 °C	and	the	absorbance	at	562 nm	measured	using	a	plate	reader	(Infinite	M200,	Tecan	UK	Ltd.,	Reading,	UK).
The	method	for	measurement	of	VEGF165	entrapment	efficiency	within	the	microspheres	was	modified	from	a	protocol	previously	described	by	Jiang	et	al.	(2002).	PLGA	microspheres	(10 mg)	were	digested	in	1 ml	of	1 mM
sodium	hydroxide	(NaOH)	for	2 h	and	then	neutralized	with	1 ml	of	1 mM	hydrochloric	acid	(HCl).	The	solution	was	then	centrifuged	(16000g,	Sigma	1–16 K)	for	15 min	at	room	temperature.	VEGF	quantification	was	achieved	using	an
ELISA	Quantikine	Kit	(R&D	Systems,	UK).	Following	the	manufacturer’s	protocol,	50 μl	of	the	assay	diluent	(RD1W)	and	200 μl	of	 the	sample	solution	were	added	into	a	pre-coated	96	well	plate	with	a	mouse	monoclonal	antibody
against	VEGF	then	incubated	for	2 h	at	room	temperature.	After	three	washes	with	buffer,	200 μl/well	of	a	horseradish	peroxidase	polyclonal	antibody	against	VEGF	was	added	for	2 h	at	room	temperature	followed	by	another	washing
step	before	a	final	incubation	for	20 min	with	200 μl/well	of	a	substrate	solution	(1:1	hydrogen	peroxide	and	TMB	chromogen).	The	reaction	was	stopped	using	50 ml	of	2 N	sulphuric	acid,	the	optical	density	was	measured	at	450 nm
using	a	plate	reader	(Infinite	M200,	Tecan	UK	Ltd.,	Reading,	UK).	VEGF	concentrations	in	the	samples	were	determined	using	a	standard	curve	of	known	concentrations	of	VEGF	supplied	with	the	kit.
2.6	Protein	release
Total	protein	release	from	earlier	publications	proved	to	be	a	reliable	method	to	characterise	release	kinetics	for	different	growth	factors	(Kirby	et	al.,	2016;	White	et	al.,	2013).	In	vitro	studies	on	the	controlled	release	of	VEGF165
encapsulated	within	microspheres	were	performed	 in	aqueous	buffers	over	3 weeks.	Aliquots	 (25 mg)	of	 the	microspheres	 (triplicate	samples	 from	each	batch)	were	suspended	 in	1 ml	phosphate	buffered	saline	 (PBS,	pH	7.4)	and
samples	were	 left	 on	 a	3-dimensional	 shaker	 (Gyrotwister,	Fisher	Scientific	UK	Ltd)	 at	 10 rpm	 in	 a	humidified	 incubator	 at	 37 °C.	Samples	were	 taken	 every	 day	 in	 the	 first	week	 then	 continued	 every	 two	days	where	 1 ml	PBS
supernatant	was	removed	and	replaced	with	 fresh	PBS.	The	removed	supernatants	were	 filtered	using	0.2 µm	filters	 then	stored	 frozen	until	 required	and	were	then	assayed	for	 total	protein	content	using	a	Micro	BCA	assay	kit.
Absorbance	values	were	correlated	to	a	standard	curve	of	HSA	in	order	to	determine	the	total	protein	content.
2.7	Proliferation	assay
Human	dermal	microvascular	endothelial	cells	(HDMEC,	passage	3	to	4)	cells	were	seeded	into	12	well	plates	pre-coated	with	gelatine	(2 ml	of	0.1%	porcine	gelatine	(Sigma,	UK)	in	PBS	at	4 °C	overnight)	at	a	density	of	25,000
cells	per	well	in	2 ml	endothelial	cell	media	(Promocell,	UK)	supplemented	with	5%	foetal	calf	serum.	Cells	were	then	treated	with	VEGF	165	(0,	3,	10,	or	30 ng/ml)	or	loaded	PLGA	microspheres	were	disinfected	by	incubation	in	a
solution	of	penicillin	and	streptomycin	(1000 IU/mL	and	1000 μg/mL	respectively	(Sigma	Aldrich,	UK))	in	PBS	at	4 °C	overnight	prior	to	use.	Microspheres	were	centrifuged	at	180g	and	washed	3x	in	PBS.	They	were	then	re-suspended
in	culture	media	at	1 mg/ml	or	3 mg/ml	final	concentration	in	Transwell	inserts	and	placed	in	the	culture	well.	After	24 h,	cells	were	stained	with	MTT	for	40 min	at	37 °C	(0.5 mg/ml	in	PBS).	After	three	gentle	washes	with	PBS,	MTT	was
eluted	in	200 µl	of	Cellusolve	(Sigma,	UK).
2.8	Assessment	of	proangiogenic	properties	of	PLGA	microspheres	loaded	with	VEGF	using	the	CAM	assay
Fertilized	chicken	(Gallus	domesticus)	eggs	were	purchased	from	Medeggs	(UK)	and	incubated	from	day	2	post-fertilization	until	day	8	at	37 °C/40%	humidity	in	an	egg	incubator	(RCOM	Suro20,	R-Com	UK).	A	square	window
(1 cm2)	was	then	cut	out	of	the	shell	using	a	Dremel	multi-tool	(Dremel,	USA)	exposing	the	CAM.	20 µl	of	PBS	containing	1 mg	of	PLGA	microspheres	was	pipetted	onto	the	CAM.	In	addition	to	untreated	eggs,	15	eggs	(each)	were
implanted	with	HSA	microspheres,	VEGF	microspheres,	or	VEGF	and	HSA	loaded	microspheres.	The	shell	window	was	resealed	with	Parafilm	(Bemis	Flexible	Packaging,	USA)	and	adhesive	tape.	Eggs	were	then	placed	at	37 °C/40%
humidity	 in	an	egg	incubator	until	day	14	post	fertilisation.	CAM	were	then	exposed	and	photographed,	after	which	CAM	were	then	retrieved,	and	the	eggs	sacrificed.	The	CAM	tissue	was	fixed	in	3.7%	paraformaldehyde	(Sigma
Aldrich,	USA)	in	dH2O	for	1 h	at	room	temperature	before	being	embedded	in	OCT	medium	(Leica,	Germany)	for	20 min	before	snap	freezing	in	liquid	nitrogen.	Sections	(20 µm)	were	cut	by	cryostat	(Leica	CM1860UV	(Leica	Germany))
and	stained	with	Haematoxylin	&	Eosin	(H&E)	according	to	the	standard	protocol	for	frozen	slides.	Slides	were	then	mounted	with	DPX	(Sigma-Aldrich,	USA)	and	imaged	at	100×	(Motic	microscope,	Motic,	China).
2.9	Statistics
All	values	presented	are	an	average	of	at	least	3	experiments,	ANOVA,	were	used	to	determine	statistical	significance,	a	P	value	of	<0.05	was	deemed	to	be	significant.
3	Results
3.1	PLGA	microsphere	characterisation	for	size,	morphology,	encapsulation	efficiency,	and	release	kinetics
In	this	study,	HSA	loaded	microspheres	were	fabricated	by	a	water	in	oil	in	water	emulsion	method.	The	different	formulations	were	made	from	PLGA	50:50	or	85:15	in	the	presence	or	absence	of	PLGA–PEG–PLGA	triblock
copolymer.	Formulation	A	(PLGA50:50),	Formulation	B	(PLGA	50:50	plus	30%	PLGA-PEG-PLGA	triblock),	formulation	C	(PLGA	85:15)	and	formulation	D	(PLGA	85:15	plus	30%	PLGA-PEG-PLGA	triblock).	The	generated	microspheres
gave	an	average	diameter	range	of	70–80	um	as	seen	in	Fig.	1A-D.	The	mean	particle	size	diameter	of	the	formulations	were	as	follow,	A	(79.6 µm ± 24.4),	B	(81.4 µm ± 23.9),	C	(70.4 µm ± 23.7),	D	(75 µm ± 24.5).
Fig.	2	A-D	show	representative	micrographs	for	the	microspheres	shape	and	morphology	from	the	different	formulations	that	show	spherical,	non-aggregated	regular	shaped	microspheres	with	a	smooth	continuous	surface.
Fig.	1	Representative	size	distribution	results	of	PLGA	microspheres	and	entrapment	efficiency	for	HSA	protein	with	average	size	diameter	for	formulations,	A	(PLGA50:50),	B	(PLGA	50:50	plus	30%	PLGA-PEG-PLGA	triblock),	C	(PLGA	85:15)	and	D	(PLGA	85:15	plus	30%	PLGA-PEG-
PLGA	triblock).
Efficient	HSA	protein	loading	within	microspheres	from	the	different	formulations	was	achieved	using	the	double	emulsion	method;	A	92%	(±2),	B-	86%	(±6),	C-	96%	(±8)	and	D-	95%	(±3).	The	in	vitro	release	kinetics	from
formulations	A-C	shows	a	traditional	biphasic	release	pattern,	which	started	with	the	initial	burst	on	day	one	and	was	followed	by	a	decline	on	day	two	then	a	lag	phase	until	the	study	ended	on	day	seven.	Different	release	profiles	were
evident	with	formulation	D	with	zero	order	release	as	seen	in	Fig.	2	E.	The	data	from	daily	HSA	release	during	the	seven-day	period	can	be	seen	in	Fig.	2	F,	there	was	a	lower	initial	burst	in	A	compared	to	other	formulations	with	an
average	daily	HSA	release	of	1.4%	(±0.7).	The	incorporation	of	triblock	copolymer	in	B	increased	the	initial	burst	to	the	highest	level	among	other	groups;	the	average	release	of	HSA	was	14%	(±10.5).	There	was	an	intermediate	burst
release	with	C	in	relation	to	other	formulations	of	interest	with	an	average	daily	release	of	5.3%	(±4.4).	A	sustained	release	profile	was	obtained	with	D	with	no	burst	and	an	average	daily	release	of	11.6%	(±1).
3.2	VEGF	release	and	bioactivity
Formulation	D	was	selected	to	achieve	a	sustained	seven	days	VEGF	release	to	induce	an	angiogenic	effect	in	the	in	ovo	CAM	model.	Therefore,	with	approximately	10%	daily	release,	the	dose	of	VEGF	loaded	microspheres	was
calculated	to	give	the	desired	release	pattern	with	an	effective	VEGF	concentration	of	10–20 ng/mg	microspheres/day	(Fig.	3).
VEGF	loaded	microspheres	were	fabricated	with	or	without	HSA	carrier	protein.	Confirmation	that	this	VEGF	was	released	in	the	therapeutic	range	was	obtained	in	subsequent	experiments	evaluating	the	biological	response
Fig.	2	Morphology	of	microspheres	and	release	kinetics.	Representative	micrographs	of	PLGA	microspheres	formulations	(A,	B,	C,	D).	Cumulative	HSA	release	for	the	formulations	over	seven	days,	data	suggest	linear	release	kinetics	for	formulation	D	with	R2 = 0.99	(E).	Daily	HSA
release	for	formulations	over	seven	day.	Results	expressed	as	mean ± SEM.
Fig.	3	Daily	VEGF	release	from	formulation	D	(PLGA	85:15	plus	30%	PLGA-PEG-PLGA	triblock)	based	on	total	protein	release	over	30 days,	with	magnified	area	for	the	first	seven	days.	Results	expressed	as	mean ± SEM.
to	the	microspheres	(Fig.	4A).	VEGF	treatment	of	HDMEC	cells	in	vitro	caused	a	dose	dependant	increase	in	the	rate	of	proliferation	between	3	and	30 ng	over	24 h,	peaking	at	an	increase	of	approximately	35%	over	control	(Fig.	4D).
Fig.	4D	also	shows	that	VEGF	associated	with	the	PLGA	microspheres	was	released	and	had	a	bioactive	effect	on	the	HDMEC	cells.	VEGF	released	from	PLGA	microspheres	caused	an	increase	in	proliferation	compared	to	HSA	only
microspheres.	This	increase	was	significant	where	the	microspheres	had	a	combination	of	HSA	and	VEGF	at	a	dose	of	1 mg/ml	but	not	3 mg/ml.	The	released	VEGF	stimulated	endothelial	cell	proliferation	to	an	extent	comparable	to	the
addition	of	VEGF	at	a	concentration	of	approximately	5 ng	per	ml.	This	was	achieved	by	delivering	microspheres	in	the	concentration	range	of	1–3 mg	per	ml.
3.3	Effect	of	the	VEGF	releasing	microspheres	on	new	blood	vessel	formation	in	ovo	using	the	CAM	assay
The	value	of	the	CAM	assay	is	that	it	shows	the	development	of	new	blood	vessels	over	seven	days	allowing	quantitation	of	the	proangiogenic	effect	of	a	treatment.	Addition	of	microspheres	induced	an	increase	in	new	blood
vessel	formation,	and	this	was	significant	when	VEGF	was	delivered	with	HSA.
VEGF	release	from	PLGA	microspheres	stimulated	an	increase	in	vessel	formation,	which	can	be	seen	in	photographs	of	the	CAM	in	Fig.	5	A	to	C.	There	is	a	visible	increase	in	both	small	and	large	vessels,	and	the	number	of
junctions	between	vessels	(an	indication	of	increased	branching)	of	the	chorioallantoic	membrane	of	fertilised	eggs.	Quantitation	of	the	numbers	of	small	and	large	vessels	and	junctions	between	the	HSA,	VEGF	and	VEGF	and	HSA
samples	is	shown	in	Fig.	5	D	to	F.	There	is	a	significant	increase	in	the	number	of	small	vessels,	large	vessels,	and	branches,	when	the	CAM	is	treated	with	PLGA	microspheres	loaded	with	HSA	and	VEGF	compared	to	HSA	alone.	PLGA
microspheres	loaded	with	only	VEGF	did	show	an	increase	in	small	vessels,	large	vessels,	and	junctions,	relative	to	HSA	loaded	PLGA	microspheres;	but	this	was	not	found	to	be	statistically	significant.	For	reference,	Fig.	5A	shows	an
example	of	the	typical	large	and	small	vessels	and	junctions.
Fig.	4	The	experimental	design	in	which	PLGA	microspheres	releasing	VEGF	were	placed	in	a	Transwell	insert	over	a	monolayer	of	HDMECs	seeded	on	gelatine	(A).	The	appearance	of	the	cells	on	gelatine	at	low	(B)	and	high	density	(C).	The	effect	of	adding	VEGF	to	HDMEC
cultures	measuring	the	increase	in	proliferation	indirectly	via	an	MTT	metabolic	essay	and	the	effect	of	microspheres	containing	HSA,	VEGF	alone	and	HSA	plus	VEGF	(D).	Results	expressed	as	mean ± SEM,	significance	determined	by	ANOVA	(aindicates	P < 0.05,).
Fig.	6	shows	H&E	stained	histology	cryosections	of	the	CAM	treated	with	PLGA	microspheres.	From	the	images	of	the	chorionic	membrane,	HSA	bearing	PLGA	microspheres	can	be	seen	as	clear	round	material	embedded	in
the	chorionic	membrane	(Fig.	6A).	Cells	can	be	seen	growing	around	but	do	not	appear	to	be	tightly	coating	the	microspheres,	there	is	a	noticeable	gap	between	the	cells	of	the	chorionic	membrane	and	the	microspheres.	In	samples
where	VEGF	or	VEGF	and	HSA	were	present,	the	microspheres	appear	to	have	a	coating	of	cells,	which	appear	to	have	the	morphology	of	epithelial	cells	(Fig.	6B	and	6C).	The	VEGF	or	VEGF	and	HSA	bearing	microspheres	appear	to
be	more	tightly	surrounded	by	cells	of	chorionic	membrane	than	the	HSA	microspheres;	there	was	no	gap	in	the	tissue	surrounding	the	microspheres.
4	Discussion
VEGF	 therapy	 is	 a	 promising	 strategy	 for	 treating	 ischemic	wound	diseases;	 however,	 the	main	 hurdle	 lies	 in	 the	 efficient	 delivery	 of	 a	 short	 living	molecule	with	 direct	 injection	 into	 the	 body.	 Silva	 and	Mooney	 (2007)
suggested	the	low	in	vivo	VEGF	concentration	due	to	the	short	half-life	could	probably	explain	the	limited	clinical	success	with	this	treatment	(Silva	and	Mooney,	2007).	To	circumvent	this	limitation,	VEGF	delivery	using	a	controlled
release	formulation	can	achieve	a	better	presentation	of	short	half-life	molecules	with	enhanced	local	concentration	and	eventually	avoiding	systemic	side	effects.	Nevertheless,	this	still	requires	a	tight	control	of	the	localised	growth
factor	delivery	(VEGF)	to	maintain	effective	therapeutic	levels	during	the	specific	period	of	treatment.	In	this	study,	our	use	of	a	delivery	system	based	on	injectable	PLGA	microspheres	attempts	to	address	some	of	the	issues	around
VEGF	use.	We	demonstrate	the	ability	of	PLGA	microspheres	to	achieve	a	therapeutic	dosage	both	in	vitro	and	in	ovo	combined	with	release	data	to	prove	that	this	therapeutic	effect	would	last	throughout	the	healing	phase	of	tissue
repair.	After	VEGF	release,	 the	breakdown	of	 the	peptide	and	 tissue	dilution	would	reduce	concentrations	 to	sub-therapeutic	 levels	as	VEGF	release	 tapers	off	and	 is	overtaken	by	 tissue	clearance/metabolism.	This	objective	was
achieved	by	using	an	engineered	formulation	of	PLGA	microspheres	with	a	release	modifier	(PLGA-PEG-PLGA	triblock	copolymer)	loaded	with	VEGF	on	a	carrier	protein	HSA.	The	VEGF	loading	was	calculated	based	on	release	kinetic
Fig.	5	In	ovo	CAM	assay	model	for	angiogenesis,	bright-field	microscopy	images	for	control	microspheres	(A)	and	microspheres	releasing	VEGF	(B&C).	Quantitation	of	the	effects	of	the	microspheres	releasing	HSA,	VEGF	or	VEGF	plus	HSA	on	the	number	of	branches/junctions
between	vessels	(D),	the	number	of	large	vessels	(E.)	and	the	small	vessels	(F).	Examples	of	each	type	of	structure	are	indicated	in	(A).	Results	expressed	as	mean ± SEM,	significance	determined	by	ANOVA	(aindicates	P < 0.05,).
Fig.	6	H&E	stained	sections	of	CAM	membranes	showing	the	growth	of	tissue	around	PLGA	microspheres	containing	HSA,	VEGF,	or	VEGF	plus	HSA.	6A	shows	the	presence	of	microspheres	with	HSA	alone	in	the	CAM	membrane.	Microspheres	are	evident	(arrows)	but	there	is	no
cellular	ingrowth	into	them.	6B	shows	the	ingrowth	of	cells	into	microspheres	containing	VEGF	and	6C	shows	the	ingrowth	of	tissue	into	microspheres	containing	VEGF	and	HSA.
from	the	carrier	protein	to	give	a	sustained	VEGF	release	for	seven	days	which	then	drops	to	sub-therapeutic	level.
The	 formulation	was	 designed	 to	 produce	 injectable	microspheres	 (∼80-µm	diameter)	 through	 a	 hypodermic	 needle	 (Qutachi	 et	 al.,	 2014).	 This	 delivery	method	 is	 a	minimally	 invasive	 technique	 for	 clinical	 applications
compared	to	 for	example	the	 intracoronary	 injection	 for	myocardial	 ischemia,	which	requires	a	major	surgical	procedure	(Henry	et	al.,	2001).	The	microspheres	can	be	also	applied	topically	using	wound	dressings	or	suitable	gel
formulation.	Furthermore,	the	size	of	the	microspheres	in	this	study	offer	a	unique	advantage	for	interstitial	growth	factor	delivery	by	avoiding	the	microspheres	internalisation	into	cells	which	is	expected	with	microspheres	in	the	size
range	of	0.1–10 µm	(He	and	Park,	2016).
For	effective	therapeutic	angiogenesis	more	attention	needs	to	be	directed	towards	the	VEGF	concentration	at	the	target	tissue	rather	than	the	dose	delivered	(Ozawa	et	al.,	2004).	The	activity	of	VEGF	to	promote	proliferation
and	migration	of	vascular	endothelial	cells	might	be	disrupted	by	the	delivery	of	VEGF	in	a	sub-	or	supra-therapeutic	dosage.	The	duration	of	therapy	can	be	another	influential	factor,	continued	delivery	after	the	required	period	could
lead	to	vessels	failing	to	become	adequately	patent,	or	 in	extreme	cases	promote	uncontrolled	over-vascularisation	leading	to	oedematous	swelling	or	bleeding	from	newly	formed	vessels	or	development	of	an	haemangioma	–	like
tumour.	Therefore	 for	 therapeutic	angiogenesis,	 the	minimum	 fluctuation	 in	VEGF	release	associated	with	zero	order	 release	kinetics	 for	 the	 required	duration	may	be	more	appropriate	 than	 the	conventional	bi/triphasic	 release
pattern	from	other	PLGA	based	formulations	(Bhardwaj	et	al.,	2008).
The	 release	mechanism	 through	 PLGA	 polymer	 reflects	 a	 complex	 interplay	 between	 drug	 diffusion	 through	 the	matrix,	 polymer	 degradation	 and	 swelling	 (Sandor	 et	 al.,	 2001).	 The	 transient	 initial	 burst	 phase	 of	 the
encapsulated	molecules	can	be	attributed	to	the	diffusion	of	surface	molecules	within	the	polymer	matrix	(Langer,	1990).	This	is	followed	by	a	sharp	decline,	which	continues	depending	on	the	polymer	characteristics	until	the	polymer
matrix	become	soft	due	to	polymer	degradation	(Park,	1995).	The	conventional	PLGA	microspheres,	might	not	be	the	best	option	for	growth	factors	delivery	due	to	the	risk	the	increased	core	acidity	rooted	to	the	degradation	by-
products	which	could	be	responsible	for	compromising	the	bioactivity	(Hines	and	Kaplan,	2013)	and	inducing	an	auto-catalytic	degradation	of	the	polymer	matrix	(Sandor	et	al.,	2001).	However,	VEGF	is	an	acid	stable	growth	factor
with	enhanced	bioactivity	at	acidic	pH	(Goerges	and	Nugent,	2004).	Furthermore,	PLGA-PEG-PLGA	triblock	copolymer	is	also	an	FDA	approved	polymer	(Chen	et	al.,	2017)	which	works	as	a	release	modifier	by	providing	hydrophilic
micro-channels	with	the	hydrophobic	polymer	matrix	to	facilitate	the	growth	factor	release	by	diffusion	and	minimise	the	accumulation	of	acidic	by	products	(Qodratnama	et	al.,	2015).	This	enhances	steady	state	release	and	appears	to
achieve	a	constant	zero	order	release	with	PLGA	85:15.
Difficulty	in	preserving	growth	factor’s	biological	activity	is	another	challenge	for	therapeutic	application.	Although	the	PLGA	matrix	provides	a	physical	protection	for	sensitive	molecules	following	injection	into	the	body,	the
payload	still	has	to	go	through	a	harsh	environment	during	microspheres	fabrication.	The	use	of	a	carrier	protein	such	as	HSA	provides	a	reliable	protection	for	the	bioactive	molecules	to	preserve	biological	activity.	Denaturation	of
growth	factors	is	expected	to	commence	at	the	interphase	between	aqueous	and	organic	solvent	during	emulsion	formation.	This	is	probably	due	to	partial	solvation	and	hence	changing	in	the	structural	confirmation	of	the	growth
factor	molecule.	The	presence	of	HSA	at	high	concentration	at	the	interphase	will	work	as	shielding	agent	at	the	interphase	and	preserve	the	growth	factor’s	biological	activity	(van	de	Weert	et	al.,	2000).
Vascularisation	is	under	tight	regulated	control	in	the	body	which	is	essential	to	prevent	hypoxia/nutrient	starvation/waste	build	up	after	tissue	damage.	The	use	of	VEGF	initially	showed	promise	as	a	therapy	but	it’s	use	and
effects	can	vary	in	the	body	with	low	or	hyper-physiological	dose	of	VEGF	leading	to	ineffective	or	malformed	leaky	vessels	as	in	haemangioma	formation	(Ozawa	et	al.,	2004).	Physiological	angiogenesis	can	be	achieved	at	20 ng/mL
which	appears	to	be	plateaued	at	50 ng/mL	(Yue	and	Tomanek,	2001).	The	PLGA	formulation	in	this	research	maintained	a	constant	release	of	VEGF	between	10	and	20 ng/mL	for	seven	days,	which	proved	to	be	effective	in	inducing
angiogenesis	in	an	in	ovo	CAM	model.
5	Conclusion
In	summary,	the	work	in	this	research	provides	a	formulation	with	engineered	release	kinetics	to	achieve	effective	VEGF	delivery	to	enhance	angiogenesis.	The	present	formulation	has	potential	as	a	treatment	for	ischemic
wound	diseases.	The	main	advantage	here	is	sustained	VEGF	delivery	at	therapeutic	concentration	with	minimum	variability	over	the	treatment	period.	The	polymer	matrix	has	been	designed	to	degrade	gradually	into	metabolites,
which	are	readily	cleared	by	the	body.
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